• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

类风湿关节炎的持续缓解:最新证据与临床考量

Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations.

作者信息

Ajeganova Sofia, Huizinga Tom

机构信息

Leids Universitair Medisch Centrum, Albinusdreef 2, Leiden, 2300 RC, The Netherlands.

Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Ther Adv Musculoskelet Dis. 2017 Oct;9(10):249-262. doi: 10.1177/1759720X17720366. Epub 2017 Aug 2.

DOI:10.1177/1759720X17720366
PMID:28974987
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5613855/
Abstract

Sustained remission is an ultimate treatment goal in the management of patients with rheumatoid arthritis (RA). Historically the frequency of sustained remission was low but the frequency of achieved sustained remission is increasing over time. The last years' clinical studies of tight control targeted treatment and intervention trials of early use of intensive strategy suggest that these treatment strategies are associated with higher rates of sustained remission. Achievement of sustained remission, in particular but not limited to early sustained remission, can provide tapering and stopping disease-modifying antirheumatic drugs (DMARDs). With new treatment strategies drug-free sustained remission is becoming an achievable goal. Sustained remission is associated with improved outcomes in regard to function, patient-reported outcomes and survival. Drug-free sustained remission is characterized by normalized function ability and survival. Sustained remission and, in particular, drug-free sustained remission offer hope that early identification of patients with arthritis, early improved novel treatments and treatment with target to achieve remission may potentially transform the progressive course of RA disease and disrupt RA chronicity. In this review we summarize the recent evidence on sustained remission in patients with RA, treatment strategies to achieve sustained remission, management of patients in sustained remission and significance of sustained remission from the patient perspective.

摘要

持续缓解是类风湿关节炎(RA)患者治疗的最终目标。从历史上看,持续缓解的发生率较低,但随着时间的推移,实现持续缓解的频率在增加。近年来,针对严格控制的临床研究、靶向治疗以及早期使用强化策略的干预试验表明,这些治疗策略与更高的持续缓解率相关。实现持续缓解,特别是但不限于早期持续缓解,可以减少并停用改善病情抗风湿药(DMARDs)。随着新的治疗策略的出现,无药持续缓解正成为一个可实现的目标。持续缓解与功能、患者报告结局和生存率的改善相关。无药持续缓解的特征是功能能力和生存率正常化。持续缓解,尤其是无药持续缓解,为早期识别关节炎患者、早期改进新型治疗方法以及以实现缓解为目标的治疗提供了希望,这可能会改变RA疾病的进展过程并打破RA的慢性病程。在本综述中,我们总结了关于RA患者持续缓解的最新证据、实现持续缓解的治疗策略、处于持续缓解状态患者的管理以及从患者角度看持续缓解的意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be3e/5613855/5b6d30b7901f/10.1177_1759720X17720366-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be3e/5613855/5b6d30b7901f/10.1177_1759720X17720366-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be3e/5613855/5b6d30b7901f/10.1177_1759720X17720366-fig1.jpg

相似文献

1
Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations.类风湿关节炎的持续缓解:最新证据与临床考量
Ther Adv Musculoskelet Dis. 2017 Oct;9(10):249-262. doi: 10.1177/1759720X17720366. Epub 2017 Aug 2.
2
Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.类风湿关节炎的疾病缓解药物停药后持续缓解:随着疾病症状的消退,越来越有可能实现这一目标。
Ann Rheum Dis. 2016 May;75(5):867-73. doi: 10.1136/annrheumdis-2014-207080. Epub 2015 May 13.
3
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.稳定缓解的类风湿关节炎患者在减少或停止抗风湿治疗时的复发率:前瞻性随机对照 RETRO 研究的中期结果。
Ann Rheum Dis. 2016 Jan;75(1):45-51. doi: 10.1136/annrheumdis-2014-206439. Epub 2015 Feb 6.
4
Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.在持续缓解的早期关节炎患者中逐渐减少传统合成 DMARDs:tREACH 试验的 2 年随访。
Ann Rheum Dis. 2016 Dec;75(12):2119-2123. doi: 10.1136/annrheumdis-2016-209272. Epub 2016 Jun 9.
5
Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.类风湿关节炎中持续停用改善病情抗风湿药缓解的患病率及预测因素:来自两个大型早期关节炎队列的结果
Arthritis Rheum. 2009 Aug;60(8):2262-71. doi: 10.1002/art.24661.
6
Defining the Optimal Strategies for Achieving Drug-Free Remission in Rheumatoid Arthritis: A Narrative Review.确定类风湿关节炎实现无药缓解的最佳策略:一项叙述性综述
Healthcare (Basel). 2021 Dec 13;9(12):1726. doi: 10.3390/healthcare9121726.
7
Remission in rheumatoid arthritis: wishful thinking or clinical reality?类风湿关节炎的缓解:一厢情愿还是临床现实?
Semin Arthritis Rheum. 2005 Dec;35(3):185-96. doi: 10.1016/j.semarthrit.2005.06.003.
8
Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.类风湿关节炎中生物制剂和传统 DMARD 疗法的逐渐减量:当前证据与未来方向。
Ann Rheum Dis. 2016 Aug;75(8):1428-37. doi: 10.1136/annrheumdis-2016-209201. Epub 2016 Jun 3.
9
Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.循环钙卫蛋白(S100A8/A9)在类风湿关节炎患者中较高,这些患者在抗风湿药物减量后 12 个月内复发。
Arthritis Res Ther. 2019 Dec 5;21(1):268. doi: 10.1186/s13075-019-2064-y.
10
Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications.早期类风湿关节炎的缓解诱导疗法:迄今的证据及临床意义
Ther Adv Musculoskelet Dis. 2016 Aug;8(4):107-18. doi: 10.1177/1759720X16654476. Epub 2016 Jun 13.

引用本文的文献

1
The relationship between disease activity and quality of life in rheumatoid arthritis patients: a network analysis.类风湿关节炎患者疾病活动度与生活质量的关系:一项网络分析
PeerJ. 2025 Aug 21;13:e19907. doi: 10.7717/peerj.19907. eCollection 2025.
2
Galectin-1 as a potential biomarker of rheumatoid arthritis drug effectiveness.半乳糖凝集素-1作为类风湿性关节炎药物疗效的潜在生物标志物。
Int J Immunopathol Pharmacol. 2025 Jan-Dec;39:3946320251358305. doi: 10.1177/03946320251358305. Epub 2025 Jul 18.
3
Dietary Recommendations from the Moroccan Society for Rheumatology (SMR) for Patients with Chronic Inflammatory Rheumatic Diseases.

本文引用的文献

1
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.EULAR 推荐的类风湿关节炎治疗策略:2016 年更新版
Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6.
2
2016 update of the EULAR recommendations for the management of early arthritis.2016 年更新版的 EULAR 早期关节炎管理建议。
Ann Rheum Dis. 2017 Jun;76(6):948-959. doi: 10.1136/annrheumdis-2016-210602. Epub 2016 Dec 15.
3
Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?
摩洛哥风湿病学会(SMR)针对慢性炎症性风湿病患者的饮食建议。
Mediterr J Rheumatol. 2025 Mar 31;36(1):36-49. doi: 10.31138/mjr.030624.dra. eCollection 2025 Mar.
4
Comparing nurse-led and rheumatologist-led care for rheumatoid arthritis patients: a systematic review and meta-analysis of randomized controlled trials.比较护士主导和风湿病专家主导的类风湿性关节炎患者护理:随机对照试验的系统评价和荟萃分析
Rev Esc Enferm USP. 2025 Jun 20;59:e20240186. doi: 10.1590/1980-220X-REEUSP-2024-0186en. eCollection 2025.
5
Association between rapid and sustained remission and clinician- and patient-reported outcomes in patients with rheumatoid arthritis: post hoc analysis of data from the SELECT-COMPARE study.类风湿关节炎患者快速和持续缓解与临床医生及患者报告结局之间的关联:SELECT-COMPARE研究数据的事后分析
Arthritis Res Ther. 2025 Jun 13;27(1):123. doi: 10.1186/s13075-025-03580-1.
6
The distinct transcriptomic signature of the resolution phase fibroblast-like synoviocytes supports endothelial cell dysfunction.消退期成纤维细胞样滑膜细胞独特的转录组特征支持内皮细胞功能障碍。
Commun Biol. 2025 May 30;8(1):837. doi: 10.1038/s42003-025-08250-1.
7
Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction.倍利珠单抗推进重度哮喘缓解:最新发现、当前观点及未来方向
Clin Exp Allergy. 2025 Jul;55(7):521-531. doi: 10.1111/cea.70083. Epub 2025 May 30.
8
Unlocking Asthma Remission: Key Insights From an Expert Roundtable Discussion.开启哮喘缓解之路:专家圆桌讨论的关键见解
Respirology. 2025 Jun;30(6):466-479. doi: 10.1111/resp.70047. Epub 2025 May 23.
9
Health-related quality of life among patients with rheumatoid arthritis in Zanzibar: a prospective cohort study.桑给巴尔类风湿性关节炎患者的健康相关生活质量:一项前瞻性队列研究。
Qual Life Res. 2025 May 7. doi: 10.1007/s11136-025-03974-3.
10
What We Know to Date About Early Treatment With Biologics in Severe Asthma: A Scoping Review About the Use of Biologics in Severe Asthma and Possible Parallels With Early Rheumatoid Arthritis.目前我们对重度哮喘生物制剂早期治疗的了解:关于生物制剂在重度哮喘中的应用以及与早期类风湿关节炎可能相似之处的范围综述
Open Respir Arch. 2025 Feb 28;7(2):100418. doi: 10.1016/j.opresp.2025.100418. eCollection 2025 Apr-Jun.
美国风湿病学会/欧洲抗风湿病联盟的短期和持续缓解期能否预测总体损伤进展较低的早期类风湿关节炎患者的功能和影像学结局?
Arthritis Care Res (Hoboken). 2017 Jul;69(7):989-996. doi: 10.1002/acr.23112. Epub 2017 Jun 7.
4
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.托珠单抗、甲氨蝶呤或二者联合治疗早期类风湿关节炎(U-Act-Early):一项多中心、随机、双盲、双模拟、策略试验。
Lancet. 2016 Jul 23;388(10042):343-355. doi: 10.1016/S0140-6736(16)30363-4. Epub 2016 Jun 7.
5
Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.在持续缓解的早期关节炎患者中逐渐减少传统合成 DMARDs:tREACH 试验的 2 年随访。
Ann Rheum Dis. 2016 Dec;75(12):2119-2123. doi: 10.1136/annrheumdis-2016-209272. Epub 2016 Jun 9.
6
Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.类风湿关节炎中生物制剂和传统 DMARD 疗法的逐渐减量:当前证据与未来方向。
Ann Rheum Dis. 2016 Aug;75(8):1428-37. doi: 10.1136/annrheumdis-2016-209201. Epub 2016 Jun 3.
7
Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial.10 年强化达标治疗后新诊断类风湿关节炎患者的长期结局:一项随机试验
Ann Intern Med. 2016 Apr 19;164(8):523-31. doi: 10.7326/M15-0919. Epub 2016 Mar 1.
8
Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden.持续缓解可改善类风湿关节炎患者的身体功能,应作为治疗目标:来自瑞典南部的一项前瞻性观察队列研究。
J Rheumatol. 2016 Jun;43(6):1017-23. doi: 10.3899/jrheum.150995. Epub 2016 Apr 1.
9
Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.早期缓解是大多数初治类风湿关节炎患者切实可行的目标。
J Rheumatol. 2016 Apr;43(4):699-706. doi: 10.3899/jrheum.141480. Epub 2016 Feb 15.
10
Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study).旨在使早期关节炎患者实现无药缓解的疾病活动评分(DAS)缓解导向治疗策略的两年结果(IMPROVED研究)
Arthritis Res Ther. 2016 Jan 21;18:23. doi: 10.1186/s13075-015-0912-y.